Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cipher Pharmaceuticals Inc. (T:CPH)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 5750 Explorer Drive,, Suite 404
MISSISSAUGA ON L4W 0A9
Tel: N/A
Website: https://www.cipherpharma.com
IR: See website
Key People
Craig J. Mull
Chairman of the Board, Interim Chief Executive Officer
Bryan Jacobs
Chief Financial Officer
Diane Gajewczyk
Vice President - Scientific and Medical Affairs
Business Overview
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.
Financial Overview
For the nine months ended 30 September 2023, Cipher Pharmaceuticals Inc revenues increased 3% to $16.2M. Net income increased 83% to $12.7M. Revenues reflect Licensing revenue increase of 13% to $6.9M. Net income benefited from Interest income increase from $197K to $1.3M (income), Unrealized foreign exchange loss (gain) increase from $130K (expense) to $21K (income).
Employees: 6 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $144.64M as of Sep 30, 2023
Annual revenue (TTM): $28.61M as of Sep 30, 2023
EBITDA (TTM): $15.60M as of Sep 30, 2023
Net annual income (TTM): $43.84M as of Sep 30, 2023
Free cash flow (TTM): $20.36M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 23,988,491 as of Jan 10, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization